Abstracts tagged "axial spondyloarthritis"

Abstract Number: 0052 • ACR Convergence 2021
HLA-B27 Is Associated with Altered Mucosal IgA Response to Oral and Fecal Microbiota in Patients with Axial Spondyloarthritis
Tejpal Gill¹, Patrick Stauffer¹, Mark Asquith¹, Ted Laderas¹, Tammy Martin², Sean Davin¹, Claire Ramirez¹, Ingrid Lindquist¹, Justine Nguyen¹, stephen Planck¹, Carley Shaut¹, Sarah Diamond¹, James T. Rosenbaum³ and Lisa Karstens¹, ¹Oregon Health & Science University, Portland, OR, ²Departments of Ophthalmology, and Molecular Microbiology & Immunology, Oregon Health & Sciences University, Portland, OR, ³Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Axial spondyloarthritis (AxSpA) is immune-mediated inflammatory arthritis, which affects the sacroiliac and spinal joints, and is associated with gut inflammation. Disease pathogenesis is associated…
Abstract Number: 0358 • ACR Convergence 2021
Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey
Uta Kiltz¹, Kirsten Hoeper², Ludwig Hammel³, Sebastian Lieb⁴, Andreas Haehle⁴ and Dirk Meyer-Olson⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Regionales Kooperatives Rheumazentrum Niedersachsen e. V.; Medizinische Hochschule Hannover, Department of Rheumatology and Immunology, Hannover, Germany,, Hannover, Germany, ³Deutsche Vereinigung Morbus Bechterew e.V.,, Schweinfurt, Germany, ⁴Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, ⁵m&i Fachklinik Bad Pyrmont, Hannover, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition often associated with impaired working participation1 not only translating to devastating outcomes for patients (pts) but…
Abstract Number: 0385 • ACR Convergence 2021
The Diagnostic Utility of Serum interleukin-22 in Patients with Suspected Axial Spondyloarthritis
Michal Sagiv¹, Abid Awisat², Aniela Shouval², Regina Peri³, Mohammad Adawi⁴, Firas Sabbah⁴, Itzhak Rosner², Aharon Kessel³ and Gleb Slobodin², ¹Faculty of Medicine, Bar Ilan University, Tel Aviv, Israel, ²Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel, ³Clinical Immunology and Allergy Division, Bnai Zion Medical Center, Haifa, Israel, ⁴Puria Medical Center, Tiberias, Israel
Background/Purpose: There is an unmet need for a reliable biomarker for the diagnosis and differentiation of AxSpA from its multiple mimickers. Serum levels of IL-22,…
Abstract Number: 0620 • ACR Convergence 2021
Is There a Difference in Disease Activity Between Genders in Axial Spondyloarthritis? 6-year Longitudinal Data from a Large National Cohort
krystel aouad¹, Anne Tournadre², Florian LUCASSON¹, Daniel Wendling³, Anna Molto⁴, Bruno Fautrel⁵ and Laure Gossec⁶, ¹Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, ²Rheumatology Department, Université Clermont Auvergne, CHU Clermont-Ferrand, INRAE, UNH UMR 1019, Clermont-Ferrand, France, ³Service de rhumatologie, CHU de Besançon, Besançon, France, ⁴Rheumatology department, Cochin hospital, APHP, Paris, France, ⁵Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ⁶Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France
Background/Purpose: Recent data suggest differences between men and women with axial spondyloarthritis (axSpA), in terms of disease activity, disease progression and treatment response [1-3]. Overall,…
Abstract Number: 0739 • ACR Convergence 2021
Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
Uta Kiltz¹, Eerik Ahomaa², Björn Buehring¹, Xenofon Baraliakos¹, David Kiefer¹, Jaclyn-Dalisay Leicht¹ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany
Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…
Abstract Number: 0745 • ACR Convergence 2021
Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Ayman Askari¹, Marc Schmalzing², Slawomir Jeka³, Javier De Toro Santos⁴, Eduardo Collantes-Estevez⁵, Fabricio Furlan⁶, Sohaib Hachaichi⁶ and Herbert Kellner⁷, ¹The Robert Jones and Agnes Hunt Orthopaedic Hospital, Shropshire, United Kingdom, ²Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Wuerzburg, Wuerzburg, Germany, ³Clinic and Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Toruń, Bydgoszcz, Poland, ⁴University Hospital Coruña, Servicio de Reumatología, A Coruña, Galicia, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁷Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany
Background/Purpose: GP2015 is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with GP2015 treatment…
Abstract Number: 0906 • ACR Convergence 2021
Measurement of Vertebral Hounsfield Units in Low Dose Computed Tomography – a Reliable Methodology for Assessing Bone Mineral Density at the Vertebral Level in Patients with Radiographic Axial Spondyloarthritis
Mary Lucy Marques¹, Nuno Pereira da Silva², Désirée van der Heijde³, Floris van Gaalen¹ and Sofia Ramiro¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Radiology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Bone loss paradoxically coexists with bone formation in radiographic axial spondyloarthritis (r-axSpA). Assessing bone mineral density (BMD) in r-axSpA poses challenges, namely because of…
Abstract Number: 0924 • ACR Convergence 2021
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Désirée van der Heijde¹, Atul Deodhar², Walter Maksymowych³, Joachim Sieper⁴, Filip Van den Bosch⁵, Tae-Hwan Kim⁶, Mitsumasa Kishimoto⁷, Andrew Ostor⁸, Bernard Combe⁹, Yunxia Sui¹⁰, Yuanyuan Duan¹¹, Alvina D. Chu¹¹ and In-Ho Song¹², ¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ²Oregon Health & Science University, Portland, OR, ³Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ⁴Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁹Montpellier University, Montpellier, France, ¹⁰AbbVie, North Chicago, IL, ¹¹AbbVie Inc, North Chicago, ¹²AbbVie Inc., North Chicago, IL
Background/Purpose: The objective of this long-term analysis of the SELECT-AXIS 1 study was to report safety and efficacy of upadacitinib (UPA) in active AS through…
Abstract Number: 1828 • ACR Convergence 2021
Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis
Sergio Schwartzman¹, Atul Deodhar², Bernard Combe³, Ana Accioly⁴, Andris Kronbergs⁴, Boris Janos⁵, Danting Zhu⁴, David Sandoval Calderon⁴, Proton Rahman⁶ and Denis Poddubnyy⁷, ¹Self Employed 72nd Street Medical Associates, Scarsdale, NY, ²Oregon Health & Science University, Portland, OR, ³CHU Montpellier Montpellier University, Montpellier, France, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Calgary, AB, Canada, ⁶Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁷Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A approved for the treatment of psoriasis, psoriatic arthritis (PsA), active ankylosing spondylitis (AS)…
Abstract Number: L21 • 2019 ACR/ARP Annual Meeting
Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study
Atul Deodhar¹, Ricardo Blanco ², Eva Dokoupilova ³, Marleen van de Sande ⁴, Stephen Hall ⁵, Anna Wiksten ⁶, Brian Porter ⁷, Hanno Richards ⁶, Sibylle Haemmerle ⁶ and Jürgen Braun ⁸, ¹Oregon Health & Science University, Portland, OR, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³MEDICAL PLUS s.r.o., Uherske Hradiste; University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Brno, Czech Republic, ⁴Amsterdam Rheumatology and immunology Center, Department of Rheumatology and Clinical Immunology, Amsterdam UMC /University of Amsterdam, Amsterdam, Netherlands, ⁵Monash University, Melbourne, Australia, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. Patients (pts) are classified as nr-axSpA due to…
Abstract Number: 567 • 2019 ACR/ARP Annual Meeting
Worse Outcomes for Female Patients with Axial Spondyloarthropathy
Sinead Maguire¹, Gillian Fitzgerald ², Claire Sheehy ³ and Finbar O'Shea ², ¹University Hospital Waterford, Dublin, Ireland, ²St James' Hospital, Dublin, Ireland, ³University Hospital Waterford, Waterford, Ireland
Background/Purpose: Axial Spondyloarthritis(axSpA) is known to have a male predominance. There is little available literature examining affected female patients. Previous studies have included small numbers…
Abstract Number: 604 • 2019 ACR/ARP Annual Meeting
Do Illness Perceptions and Coping Change over Time in Patients Recently Diagnosed with Axial Spondyloarthritis? A 2-Year Follow-Up Study in the SPACE Cohort
Miranda van Lunteren¹, Robert B.M. Landewé ², Camilla Fongen ³, Roberta Ramonda ⁴, Désirée van der Heijde ¹ and Floris van Gaalen ¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University of Padova, Padova, Italy
Background/Purpose: We have previously shown that in patients with recently diagnosed axial SpA (axSpA), illness perceptions had a negative impact on the relationship between back…
Abstract Number: 837 • 2019 ACR/ARP Annual Meeting
Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Lykke Midtbøll Ørnbjerg ², Anne Gitte Loft ³, Tore Kvien ⁴, Adrian Ciurea ⁵, Herman Mann ⁶, Kari K. Eklund ⁷, Ayten Yazici ⁸, Maria José Santos ⁹, Johan Askling ¹⁰, Ziga Rotar ¹¹, Bjorn Gudbjornsson ¹², Manuel Pombo-Suarez ¹³, Catalin Codreanu ¹⁴, Irene van der Horst-Bruinsma ¹⁵, Eirik Kristianslund ¹⁶, Michael J. Nissen ¹⁷, Karel Pavelka ⁶, Nina Trokovic ¹⁸, Nevsun Inanc ¹⁹, Elsa Vieira-Sousa ²⁰, Daniela DiGuiseppe ²¹, Matija Tomsic ²², Arni Jon Geirsson ²³, Ruxandra IONESCU ²⁴, Marleen van de Sande ²⁵, Florenzo Iannone ²⁶, Carlos Sánchez-Piedra ²⁷, Gareth Jones ²⁸, Lise Hyldstrup ², Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵University Hospital Zürich, Zürich, Switzerland, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁷ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ⁸Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Karolinska Institutet, Stockholm, Sweden, ¹¹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹²Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁷University Hospital Geneva, Geneva, Switzerland, ¹⁸Helsinki University Central Hospital, Helsinki, Finland, ¹⁹Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, ²⁰Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²¹Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ²²Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁴SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁵Amsterdam UMC, Amsterdam, Netherlands, ²⁶Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁷Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²⁸University of Aberdeen, Aberdeen, United Kingdom, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common.1 However, the impact of such discordance on retention and remission rates…
Abstract Number: 1487 • 2019 ACR/ARP Annual Meeting
Impact of TNF-α Inhibitor on Lipid Profile and Atherogenic Index of Plasma in Axial Spondyloarthritis: Two-year Follow-up Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Hong Ki Min¹, Seung-Ki Kwok ² and Sang-Heon Lee ¹, ¹Konkuk university medical center, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: To evaluate the influence of TNF-α inhibitor on lipid profile and atherogenic index of plasma (AIP) in axial spondyloarthritis (axSpA) patients with long term…
Abstract Number: 1548 • 2019 ACR/ARP Annual Meeting
Drug Survival of Secukinumab for Axial Spondyloarthritis in a Real-World Setting Possible Response Factors
Carolina Merino Argumanez¹, Valentina Emperiale ², María Martín ³, Marta Valero ⁴, javier Bachiller ⁵, Beatriz Joven-Ibáñez ⁶, Ana Pérez-Gómez ⁷ and Jose Campos ¹, ¹Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, ²Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ³Hospital Universitario Doce de Octubre, Madrid, Spain, ⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁵Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
Background/Purpose: Secukinumab is a newly introduced biologic therapy against IL-17 which has been proved effective in patients with ankylosing spondylitis (AS) in clinical trials and…

1
2
3
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].